388 related articles for article (PubMed ID: 25482492)
1. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
2. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.
Ramakrishnan S; Ku S; Ciamporcero E; Miles KM; Attwood K; Chintala S; Shen L; Ellis L; Sotomayor P; Swetzig W; Huang R; Conroy D; Orillion A; Das G; Pili R
BMC Cancer; 2016 Aug; 16():617. PubMed ID: 27506904
[TBL] [Abstract][Full Text] [Related]
3. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Waltregny D; North B; Van Mellaert F; de Leval J; Verdin E; Castronovo V
Eur J Histochem; 2004; 48(3):273-90. PubMed ID: 15590418
[TBL] [Abstract][Full Text] [Related]
4. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
5. Histone deactylase gene expression profiles are associated with outcomes in blunt trauma patients.
Sillesen M; Bambakidis T; Dekker SE; Fabricius R; Svenningsen P; Bruhn PJ; Svendsen LB; Hillingsø J; Alam HB
J Trauma Acute Care Surg; 2016 Jan; 80(1):26-32; discussion 32-3. PubMed ID: 26517778
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
[TBL] [Abstract][Full Text] [Related]
8. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
9. Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
Kim JH; Moon SH; No M; Kim JJ; Choi EJ; Cho BJ; Kim JS; Kim IH; Kim IA
Cancer Res Treat; 2016 Jul; 48(3):1130-40. PubMed ID: 26582395
[TBL] [Abstract][Full Text] [Related]
10. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
11. Rapid changes in expression of class I and IV histone deacetylases during epileptogenesis in mouse models of temporal lobe epilepsy.
Jagirdar R; Drexel M; Kirchmair E; Tasan RO; Sperk G
Exp Neurol; 2015 Nov; 273():92-104. PubMed ID: 26238735
[TBL] [Abstract][Full Text] [Related]
12. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma.
Adams H; Fritzsche FR; Dirnhofer S; Kristiansen G; Tzankov A
Expert Opin Ther Targets; 2010 Jun; 14(6):577-84. PubMed ID: 20415600
[TBL] [Abstract][Full Text] [Related]
13. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.
Ishihama K; Yamakawa M; Semba S; Takeda H; Kawata S; Kimura S; Kimura W
J Clin Pathol; 2007 Nov; 60(11):1205-10. PubMed ID: 17720775
[TBL] [Abstract][Full Text] [Related]
14. Proteomics-based trapping with single or multiple inactive mutants reproducibly profiles histone deacetylase 1 substrates.
Herath KE; Kodikara IKM; Pflum MKH
J Proteomics; 2023 Mar; 274():104807. PubMed ID: 36587730
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Marquard L; Poulsen CB; Gjerdrum LM; de Nully Brown P; Christensen IJ; Jensen PB; Sehested M; Johansen P; Ralfkiaer E
Histopathology; 2009 May; 54(6):688-98. PubMed ID: 19438744
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
Huang R; Zhang X; Sophia S; Min Z; Liu X
Anticancer Drugs; 2018 Apr; 29(4):364-370. PubMed ID: 29481474
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Sakuma T; Uzawa K; Onda T; Shiiba M; Yokoe H; Shibahara T; Tanzawa H
Int J Oncol; 2006 Jul; 29(1):117-24. PubMed ID: 16773191
[TBL] [Abstract][Full Text] [Related]
18. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
Morine Y; Shimada M; Iwahashi S; Utsunomiya T; Imura S; Ikemoto T; Mori H; Hanaoka J; Miyake H
Surgery; 2012 Mar; 151(3):412-9. PubMed ID: 21982637
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.
Osada H; Tatematsu Y; Saito H; Yatabe Y; Mitsudomi T; Takahashi T
Int J Cancer; 2004 Oct; 112(1):26-32. PubMed ID: 15305372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
